Table 2.
Model inputs: estimated annual prevalence and incidence rates (%); dose and annual number of doses of infliximab used
| % | RA | AS | CD | UC | Psoriasis | PsA |
|---|---|---|---|---|---|---|
| Prevalencea/incidence | ||||||
| Germany | 1.13/0.035b | 0.09/0.007c | 0.13/0.005 [51] | 0.06/0.004 [52] | 2.28/0.120d | 0.69/0.104e |
| UK | 1.02/0.035b | 0.10/0.007c | 0.16/0.009 [51] | 0.22/0.012 [52] | 1.51/0.140 [53] | 0.11/0.017 [54] |
| Italy | 0.31/0.098 [55] | 0.09/0.007c | 0.09/0.002 [51] | 0.12/0.008 [52] | 1.15/0.230 [56] | 0.12/0.019e |
| The Netherlands | 1.02/0.035b | 0.09/0.007c | 0.12/0.007 [51] | 0.05/0.013 [52] | 2.14/0.120 [57] | 0.64/0.097e |
| Belgium | 1.07/0.035b | 0.09/0.007c | 0.12/0.004 [51] | 0.05/0.013h | 2.14/0.120d | 0.65/0.098e |
| Dose | 3 mg/kg | 5 mg/kg | 5 mg/kg | 5 mg/kg | 5 mg/kg | 5 mg/kg |
| No. of doses (switch) | 6.5 | 7.43 | 6.5 | 6.5 | 6.5 | 6.5 |
| No. of doses (naïve)f | 8.75 | 9.57g | 8.75 | 8.75 | 8.75 | 8.75 |
Where a reference source gave a range, a mid-point estimate was used. Values shown have been rounded to the third decimal point
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
aEpi Database®. Kantar Health. Data on file
bMusculoskeletal Health in Europe Report v5 [58]. A mean value of the range given (derived from published literature) was used
cTaken from [59], supported by [60]. The consistent data from two such different locations suggest that this incidence rate is likely to be consistent across North America and Europe
dThe incidence for Germany and the UK was assumed to be the same as for The Netherlands
eFor these countries, the incidence was calculated from the UK incidence, weighted based on the prevalence in the respective country
fIncluding one loading dose
gThe SPC indicated that maintenance doses should be administered every 6–8 weeks; therefore, 7 weeks was used for the purpose of this model
hData from The Netherlands were used as proxy